Probiotics for the Prevention of Pediatric Antibiotic-Associated Diarrhea

Explore: The Journal of Science and Healing

Volumn 12, Issue 6, 2016, Pages 463-466

  Hayes, Shelby R ^a   Vargas, Ashley J ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

METRONIDAZOLE; PROBIOTIC AGENT; VANCOMYCIN; ANTIINFECTIVE AGENT;

ABDOMINAL PAIN; ANTIBIOTIC ASSOCIATED DIARRHEA; ARTICLE; ATTRIBUTABLE RISK; BIFIDOBACTERIUM; BLOATING; CHILDHOOD DISEASE; CINAHL; CLOSTRIDIUM BUTYRICUM; CONSTIPATION; DIETARY SUPPLEMENT; DRUG EFFICACY; DRUG INDUSTRY; DRUG SAFETY; EMBASE; FLATULENCE; FOLLOW UP; HUMAN; INCIDENCE; LACTOCOCCUS; LEUCONOSTOC; LEUCONOSTOC CREMORIS; MEDLINE; NAUSEA; PRIORITY JOURNAL; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; SACCHAROMYCES; SYSTEMATIC REVIEW; TASTE DISORDER; THORAX PAIN; VOMITING; WEB OF SCIENCE; CHEMICALLY INDUCED; CHILD; DIARRHEA; GASTROINTESTINAL TRACT;

ANTI-BACTERIAL AGENTS; CHILD; DIARRHEA; DIETARY SUPPLEMENTS; GASTROINTESTINAL TRACT; HUMANS; PROBIOTICS;

EID: 84999039997     PISSN: 15508307     EISSN: 18787541     Source Type: Journal    
DOI: 10.1016/j.explore.2016.08.015     Document Type: Article

References (18)

1. 1 Turck, D., Bernet, J.-P., Marx, J., et al. Incidence and risk factors of oral antibiotic-associated diarrhea in an outpatient pediatric population. J Pediatr Gastroenterol Nutr 37:1 (2003), 22–26, 10.1097/00005176-200307000-00004.
2. 2 McFarland, L.V., Ozen, M., Dinleyici, E.C., Goh, S., Comparison of pediatric and adult antibiotic-associated diarrhea and Clostridium difficile infections. World J Gastroenterol 22:11 (2016), 3078–3104, 10.3748/wjg.v22.i11.3078.
3. 3 Surawicz, C.M., Brandt, L.J., Binion, D.G., et al. Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections. Am J Gastroenterol 108:4 (2013), 478–498, 10.1038/ajg.2013.4.
4. 4 Schutze, G.E., Willoughby, R.E., Committee on Infectious Diseases, & American Academy of Pediatrics. Clostridium difficile infection in infants and children. Pediatrics 131:1 (2013), 196–200, 10.1542/peds.2012-2992.
5. 5 Koenig, J.E., Spor, A., Scalfone, N., et al. Succession of microbial consortia in the developing infant gut microbiome. Proc Natl Acad Sci U S A 108:suppl (2011), 4578–4585, 10.1073/pnas.1000081107.
6. 6 Korpela, K., Salonen, A., Virta, L.J., Kekkonen, R.A., de Vos, W.M., Association of early-life antibiotic use and protective effects of breastfeeding: role of the intestinal microbiota. JAMA Pediatr, 2016, 10.1001/jamapediatrics.2016.0585.
7. 7 Mbakwa, C.A., Scheres, L., Penders, J., Mommers, M., Thijs, C., Arts, I.C.W., Early life antibiotic exposure and weight development in children. J Pediatr, 2016, 10.1016/j.jpeds.2016.06.015.
8. 8 Wu, P., Feldman, A.S., Rosas-Salazar, C., et al. Relative importance and additive effects of maternal and infant risk factors on childhood asthma. PLoS One, 11(3), 2016, e0151705, 10.1371/journal.pone.0151705.
9. 9 Floch MH, Walker WA, Sanders, ME, et al. Recommendations for probiotic use—2015 update: proceedings and consensus opinion. J Clin Gastroenterol. n.d.; 49(suppl 1): S69–S73. 〈doi:10.1097/MCG.0000000000000420〉.
10. 10 Johnston, B.C., Supina, A.L., Ospina, M., Vohra, S., Probiotics for the prevention of pediatric antibiotic-associated diarrhea. Vohra, S., (eds.) Cochrane Database of Systematic Reviews, 2007, John Wiley & Sons, Ltd, Chichester, UK, 10.1002/14651858.CD004827.pub2.
11. 11 Johnston, B.C., Goldenberg, J.Z., Vandvik, P.O., Sun, X., Guyatt, G.H., Probiotics for the prevention of pediatric antibiotic-associated diarrhea. Cochrane Database Syst Rev, 11, 2011, CD004827, 10.1002/14651858.CD004827.pub3.
12. 12 Alfaleh, K., Anabrees, J., Bassler, D., Al-Kharfi, T., Probiotics for prevention of necrotizing enterocolitis in preterm infants. Cochrane Database Syst Rev, 3, 2011, CD005496, 10.1002/14651858.CD005496.pub3.
13. 13 Guyatt, G.H., Oxman, A.D., Kunz, R., et al. What is “quality of evidence” and why is it important to clinicians?. BMJ 336:7651 (2008), 995–998, 10.1136/bmj.39490.551019.BE.
14. 14 Clarke, M., Standardising outcomes for clinical trials and systematic reviews. Trials, 8, 2007, 39, 10.1186/1745-6215-8-39.
15. 15 Ioannidis, J.P.A., Evans, S.J.W., Gøtzsche, P.C., et al. Better reporting of harms in randomized trials: an extension of the CONSORT statement. Ann Intern Med 141:10 (2004), 781–788 〈http://www.ncbi.nlm.nih.gov/pubmed/15545678〉.
16. 16 Johnston, B.C., Shamseer, L., da Costa, B.R., Tsuyuki, R.T., Vohra, S., Measurement issues in trials of pediatric acute diarrheal diseases: a systematic review. Pediatrics 126:1 (2010), e222–e231, 10.1542/peds.2009-3667.
17. 17 Hoffmann, D.E., Fraser, C.M., Palumbo, F.B., et al. Science and regulation. Probiotics: finding the right regulatory balance. Science 342:6156 (2013), 314–315, 10.1126/science.1244656.
18. 18 Sanders ME, Akkermans LMA, Haller D, et al. Safety assessment of probiotics for human use. Gut Microbes n.d.; 1(3):164–185. 〈doi:10.4161/gmic.1.3.12127〉.